Comparative activity of carbapenem testing (the COMPACT study) in Turkey by Leblebicioglu, Hakan et al.
RESEARCH ARTICLE Open Access
Comparative activity of carbapenem testing (the
COMPACT study) in Turkey
Hakan Leblebicioglu
1*, Nedim Cakir
2, Mustafa Celen
3, Halil Kurt
4, Hakan Baris
5 and Joerg Laeuffer
6, for
Turkish COMPACT Study Group
Abstract
Background: Recent evidence indicates that Gram-negative bacterial pathogens, the most common of which are
Pseudomonas spp., Enterobacteriaceae, and Acinetobacter baumannii, are frequent causes of hospital-acquired
infections. This study aims to evaluate the in vitro activity of doripenem and comparator carbapenem antibiotics
against Gram-negative clinical isolates collected from COMParative Activity of Carbapenem Testing (COMPACT)
study centres in Turkey.
Methods: Ten centres in Turkey were invited to submit Pseudomonas aeruginosa, Enterobacteriaceae, and other
Gram-negative isolates from intensive care unit (ICU)/non-ICU patients with complicated intra-abdominal infections,
bloodstream infections, or nosocomial pneumonia, including ventilator-associated pneumonia, between May and
October 2008. Susceptibility was determined by each centre using E-test. A central laboratory performed species
confirmation as well as limited susceptibility and quality-control testing.
Results: Five hundred and ninety six isolates were collected. MIC90 values for doripenem, meropenem, and
imipenem, respectively, were 32, ≥ 64, and ≥ 64 mg/L against Pseudomonas spp.; 0.12, 0.12, and 0.5 mg/L against
Enterobacteriaceae; and ≥ 64 mg/L for each against other Gram-negative isolates. In determining the susceptibility
of hospital isolates of selected Gram-negative pathogens to doripenem, imipenem, and meropenem, we found
that against all pathogens combined, the MIC90 for ICU compared with non-ICU isolates was higher.
Conclusions: Doripenem showed similar or slightly better activity than meropenem and better activity than
imipenem against the Gram-negative pathogens collected in Turkey.
Background
Modified treatment practices towards improving in-hos-
pital patient care and reducing the development and
spread of resistant strains begin with the surveillance of
known infection-causing pathogens. Isolates of particular
importance within the hospital setting are Pseudomonas
spp. and Enterobacteriaceae, as well as other Gram nega-
tives such as Acinetobacter baumannii (A.baumannii).
Recent evidence indicates these pathogens are common
causes of infection, including complicated intra-abdom-
inal infection (cIAI), blood stream infection (BSI), and
nosocomial pneumonia (NP). Escherichia coli (E. coli),
for example, is the most common cause of BSIs in
England, accounting for 18% of such infections [1].
Surveillance results from the 2007 Meropenem Yearly
Susceptibility Test Information Collection (MYSTIC)
show ongoing resistance across Europe for these Gram-
negative pathogens [2]. Acinetobacter spp. also play an
increasing role in healthcare-associated infections [1]. In
Turkey, for example, susceptibility of A. baumannii to
imipenem decreased from 80.4% in 2000 to 40.0% in
2006 and from 71.7% to 40.0% for meropenem during
the same time period [3].
Doripenem is a carbapenem antibiotic with activity simi-
lar to imipenem and ertapenem against Gram-positive
cocci, and similar to meropenem against Gram-negative
pathogens [4]. Doripenem was approved in the European
Union on July 25, 2008, for NP, including ventilator-asso-
ciated pneumonia (VAP), cIAIs, and complicated urinary
tract infections [5].
The COMParative Activity of Carbapenem Testing
(COMPACT) Study was conducted to evaluate the in
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antibiotics against recent Gram-negative clinical isolates;
specifically Pseudomonas spp., Enterobacteriaceae,a n d
other Gram negatives, including A. baumannii.T h i s
report focuses on the results from centres in Turkey
and compares them with the general susceptibility pat-
tern observed in COMPACT centres across Europe, the
Middle East, and Africa.
Methods
Isolates of Pseudomonas aeruginosa, Enterobacteriaceae,
and other Gram negatives were collected prospectively
between May 2008 and June 2009 from 80 centres
across 16 countries in Europe, the Middle East, and
Africa, including 10 centres in Turkey. Each centre was
asked to prospectively collect 60 non-duplicate Gram-
negative isolates. Isolates were obtained from intensive
care unit (ICU) and non-ICU patients hospitalised with
1 of 3 types of infection: cIAI, BSI, or NP, including
VAP. Collecting centres determined susceptibility of the
isolates to doripenem, imipenem, and meropenem using
E-test strips according to the manufacturer’s guidelines.
The study protocol was reviewed and approved by an
independent ethics committee. The study was conducted
in accordance with the principles in the Declaration of
Helsinki and was consistent with applicable regulatory
requirements.
Isolates were batched by each centre and sent to a
reference laboratory (Quotient Bioresearch Ltd., Ford-
ham, UK) for species confirmation. The reference
laboratory determined the minimum inhibitory concen-
tration (MIC) of doripenem, imipenem, and meropenem
for all isolates identified by each centre’sE - t e s ta si m i -
penem- or meropenem-resistant, according to the 2009
Clinical and Laboratory Standards Institute (CLSI)
breakpoints, or as doripenem non-susceptible by the US
Food and Drug Administration (FDA) breakpoints
(Table 1) [6]. The MIC was determined by both broth
microdilution using CLSI methodology [7] and E-test
according to the manufacturer’s methodology. Limited
susceptibility testing was performed for quality control
purposes on each centre’s E-test results by randomly
selecting 10% of the susceptible isolates from each cen-
tre. FDA breakpoints were used for doripenem since
CLSI breakpoints for doripenem were not available
when the study was initiated. Breakpoints for Enterobac-
teriaceae were subsequently released in June 2010 [8].
CLSI breakpoints were used for imipenem and merope-
nem [9] since European Committee on Antimicrobial
Susceptibility Testing (EUCAST) breakpoints were not
available when the study was initiated. However, since
EUCAST breakpoints for doripenem, imipenem, and
meropenem are now available, they are also used for
this data analysis [10].
Results
Ten centres in Turkey provided 596 eligible isolates.
Patient demographics are shown in Table 2. By pathogen
group, 297 (49.8%) were Pseudomonas spp., of which
98.7% were P. aeruginosa (49.2% of total); 240 (40.3%) iso-
lates were Enterobacteriaceae, of which 47.9% were E. coli
and 35.0% Klebsiella pneumoniae (19.3% and 14.1% of
total, respectively); 59 (9.9%) were other Gram-negative
bacteria, of which 89.8% were A. baumannii (8.9% of total)
(Table 3).
By type of infection, 42.4% of isolates were NP; 40.4%,
BSI; and 17.1%, cIAI. Slightly more than half of the iso-
lates came from patients in the ICU (51.8%), whilst
48.2% came from non-ICU patients (Table 2).
Of the 596 isolates, 187 (31.4%) were resistant to at least
one carbapenem based on the E-test results reported by
the collecting centre. Two hundred fifty-two isolates
underwent reference laboratory confirmation of the cen-
tres’ E-test results. Of the 91 determined by the centres to
be susceptible to doripenem using current FDA break-
points, 73 (80.2%) were confirmed as susceptible by the
reference laboratory. Of the 161 determined to be non-
susceptible to doripenem by the centres, 153 (95.0%) were
confirmed as non-susceptible by the reference laboratory.
For imipenem, of the 73 determined by the centres to be
susceptible using CLSI breakpoints, 68 (93.2%) were con-
firmed as susceptible. Of the 179 determined by the
Table 1 Breakpoints
Family/Genus (species) FDA CLSI EUCAST
Doripenem Imipenem/
Meropenem
Doripenem/Imipenem/
Meropenem*
Doripenem Imipenem Meropenem
SI R S I R S I R SIRSI RSI R
Pseudomonas aeruginosa ≤ 2-- ≤ 48≥ 16 ≤ 48≥ 16 ≤ 1 2-4 ≥ 8 ≤ 48≥ 16 ≤ 2 4-8 ≥ 16
Enterobacteriaceae ≤ 0.5 - - ≤ 48≥ 16 ≤ 12 ≥ 4 ≤ 1 2-4 ≥ 8 ≤ 2 4-8 ≥ 16 ≤ 2 4-8 ≥ 16
Acinetobacter spp. ≤ 1-- ≤ 48≥ 16 ≤ 48≥ 16 ≤ 1 2-4 ≥ 8 ≤ 2 4-8 ≥ 16 ≤ 2 4-8 ≥ 16
FDA US Food and Drug Administration; CLSI Clinical and Laboratory Standards Institute; EUCAST European Committee on Antimicrobial Susceptibility Testing; S
susceptible; I intermediate; R resistant
*As of June 2010
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Page 2 of 8Table 2 Isolates from Turkey by patient gender, age, location, and infection type
Number of Isolates Gender Age Group Location Infection Type
Species F M 0 to 2 yrs 3 to 5 yrs 6 to 17 yrs 18 to 64 yrs > 64 yrs ICU Non-ICU BSI cIAI NP
Acinetobacter baumannii 21 32 2 36 15 41 12 21 6 26
Acinetobacter haemolyticus 11 1 1
Acinetobacter junii/johnsonii 12 3 3 2 1
Acinetobacter lwoffii 11 1 1
Citrobacter freundii 11 1 1
Enterobacter aerogenes 3 6 7 2631 2 6
Enterobacter cloacae 2 7 1 7 1273 5 1
Escherichia coli 52 63 3 1 5 54 52 39 76 70 32 13
Klebsiella oxytoca 4 1 1 1 1 2233 2
Klebsiella pneumoniae 33 51 5 1 42 36 47 37 38 9 37
Kluyvera sp. 1 1 1 1 2 1 1
Morganella morganii 12 1 1 1 3 21
Pantoea sp. 1 1 1 1
Proteus mirabilis 2 1 111 1 1
Pseudomonas aeruginosa 113 180 18 3 7 168 97 160 133 90 40 163
Pseudomonas putida 21 1 2 3 12
Pseudomonas stutzeri 11 1 1
Raoultella terrigena 11 1 1
Serratia marcescens 2 6 1 3 4627 1
Stenotrophomonas maltophilia 11 1 1
Total 238 358 29 4 18 330 215 309 287 241 102 253
BSI bloodstream infection; cIAI complicated intra-abdominal infection; F female; ICU intensive care unit; M male; NP nosocomial pneumonia
Table 3 Isolates from Turkey by specimen source
Number of Isolates Source of Isolation
Species Pulmonary Samples Peritoneal Fluid Blood Others Grand Total
Acinetobacter baumannii 26 21 6 53
Acinetobacter haemolyticus 11
Acinetobacter junii/johnsonii 12 3
Acinetobacter lwoffii 11
Citrobacter freundii 11
Enterobacter aerogenes 61 2 9
Enterobacter cloacae 11 3 4 9
Escherichia coli 13 1 72 29 115
Klebsiella oxytoca 23 5
Klebsiella pneumoniae 37 39 8 84
Kluyvera sp. 1 1 2
Morganella morganii 21 3
Pantoea sp. 11
Proteus mirabilis 11 2
Pseudomonas aeruginosa 161 1 91 40 293
Pseudomonas putida 12 3
Pseudomonas stutzeri 1 1
Raoultella terrigena 11
Serratia marcescens 17 8
Stenotrophomonas maltophilia 1 1
Total 251 3 245 97 596
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Page 3 of 8centres to be non-susceptible (ie, intermediate or resistant)
to imipenem, 173 (96.6%) were confirmed as non-suscepti-
ble by the reference laboratory. For meropenem, of the 98
determined by the centres to be susceptible using CLSI
breakpoints, 80 (81.6%) were confirmed as susceptible. Of
the 154 determined to be non-susceptible (ie, intermediate
or resistant) to meropenem by the centres, 143 (92.9%)
were confirmed as non-susceptible by the reference
laboratory.
For P. aeruginosa,t h eM I C 90 was lowest for doripe-
nem (32 mg/L) compared with ≥ 64 mg/L for both imi-
penem and meropenem (Table 4). Only 19.5% of
P. aeruginosa isolates had a doripenem MIC > 4 mg/L
compared with 25.8% and 30.9% for meropenem and
imipenem, respectively (Figure 1, Tables 5, 6, 7). At
MIC 2 mg/L (the FDA breakpoint for doripenem),
64.0% of Pseudomonas spp. were susceptible to doripe-
nem, 48.2% to imipenem, and 56.2% to meropenem. At
MIC ≤ 4 mg/L (the CLSI breakpoint for imipenem and
meropenem), 74.1% were susceptible to doripenem,
53.9% to imipenem, and 63.0% to meropenem.
For Enterobacteriaceae, doripenem and meropenem
were equally active (MIC90 0.12 mg/L) and at least four-
fold more active than imipenem (MIC90 0.5 mg/L;
Figure 2). At MIC 0.5 mg/L (the FDA breakpoint for
doripenem against Enterobacteriaceae), 97.5% were sus-
ceptible to doripenem, 93.75% to imipenem, and 97.5%
to meropenem. At MIC ≤ 4 mg/L (the 2009 CLSI break-
point for imipenem and meropenem against Enterobac-
teriaceae), 98.75% were susceptible to doripenem,
98.33% to imipenem, and 98.75% to meropenem. At
MIC ≤ 1 mg/L (the new breakpoint for imipenem and
meropenem, as well as doripenem, against Enterobacter-
iaceae established by CLSI in June 2010), 97.92% were
susceptible to doripenem, 96.67% to imipenem and
97.92% to meropenem. Also at MIC ≤ 1m g / L ,1 0 0 %o f
E. coli and 94.1% of K. pneumoniae were susceptible to
each of the three carbapenems. The MIC90 for all three
carbapenems against other Gram-negative isolates,
including A. baumannii (Figure 3), was ≥ 64 mg/L.
Based on the newly established EUCAST breakpoints
for carbapenems (Table 1), 43.4% of Pseudomonas spp.
and 2.1% of Enterobacteriaceae isolates were deemed
doripenem non-susceptible according to the E-test MIC
results from the collecting centres (Table 8). Regarding
Pseudomonas spp., 46.1% were non-susceptible to imipe-
nem and 43.8% to meropenem, whilst 2.1% and 1.7% of
Enterobacteriaceae were non-susceptible to imipenem
and meropenem, respectively.
Discussion
The COMPACT surveillance study involving 10 centres
in Turkey demonstrated that doripenem has similar or
slightly better activity than imipenem and meropenem
against Pseudomonas spp., Enterobacteriaceae, and other
Gram-negative pathogens.
Compared with the other European, Middle Eastern,
and African countries that participated in COMPACT,
Turkey had a high rate (31.4%) of combined imipenem
resistance, meropenem resistance, or doripenem non-sus-
c e p t i b i l i t y[ 1 1 ] .T h i sr a t ei nT u r k e yw a ss e c o n do n l yt o
Russia (33.6%), and followed by Egypt (28.3%), Spain
(23.6%), Italy (23.2%) and the remainder of the 16 coun-
tries involved.
In Turkey, doripenem was the most active of the 3
carbapenems against Pseudomonas spp. The non-sus-
ceptible (intermediate and resistant) rate of 46.1% for
Pseudomonas spp. (98.7% P. aeruginosa) to imipenem
observed in this study is higher than the 32% observed
Table 4 Minimum inhibitory concentration (MIC) of all
pathogens combined and pathogen groups from Turkey
for doripenem, imipenem and meropenem
Turkey N MIC (mg/L)
Minimum 50% 90% Maximum
All pathogens 596
Doripenem 0.008 0.12 32 ≥ 64
Imipenem 0.06 1 ≥ 64 ≥ 64
Meropenem 0.008 0.25 ≥ 64 ≥ 64
Pseudomonas spp. 297
Doripenem 0.03 1 32 ≥ 64
Imipenem 0.12 4 ≥ 64 ≥ 64
Meropenem 0.03 1 ≥ 64 ≥ 64
Enterobacteriaceae 240
Doripenem 0.008 0.03 0.12 32
Imipenem 0.12 0.25 0.5 ≥ 64
Meropenem 0.008 0.03 0.12 ≥ 64
Other Gram negatives 59
Doripenem 0.03 8 ≥ 64 ≥ 64
Imipenem 0.06 32 ≥ 64 ≥ 64
Meropenem 0.06 32 ≥ 64 ≥ 64
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Figure 1 Cumulative% minimum inhibitory concentration (MIC)
distributions against Pseudomonas aeruginosa (N = 293).
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Page 4 of 8Table 5 Isolates from Turkey: Doripenem MIC distribution
Number of isolates Doripenem E-test MIC (mg/L)
Species 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 > 32 Grand Total
Acinetobacter baumannii 1 1 1537737 1 8 5 3
Acinetobacter haemolyticus 11
Acinetobacter junii/johnsonii 11 1 3
Acinetobacter lwoffii 11
Citrobacter freundii 1 1
Enterobacter aerogenes 34 2 9
Enterobacter cloacae 13 4 1 9
Escherichia coli 9 5 9 3 7 413 2 1 1 5
Klebsiella oxytoca 32 5
Klebsiella pneumoniae 22 7 3 5 1 0 1 3 1 2 1 1 1 8 4
Kluyvera sp. 1 1 2
Morganella morganii 111 3
Pantoea sp. 1 1
Proteus mirabilis 11 2
Pseudomonas aeruginosa 6 1 95 33 7 2 9 2 2 2 2 2 8 3 0 1 3 1 3 2 1 2 9 3
Pseudomonas putida 12 3
Pseudomonas stutzeri 11
Raoultella terrigena 1 1
Serratia marcescens 413 8
Stenotrophomonas maltophilia 11
Grand Total 12 95 96 38 64 47 33 29 28 38 38 17 21 40 596
Table 6 Isolates from Turkey: Imipenem MIC distribution
Number of isolates Imipenem E-test MIC (mg/L)
Species 0.06 0.12 0.25 0.5 1 2 4 8 16 32 > 32 Grand Total
Acinetobacter baumannii 2 3 4 3 1 1 15 24 53
Acinetobacter haemolyticus 1 1
Acinetobacter junii/johnsonii 12 3
Acinetobacter lwoffii 11
Citrobacter freundii 11
Enterobacter aerogenes 15 3 9
Enterobacter cloacae 14 3 1 9
Escherichia coli 36 69 9 1 115
Klebsiella oxytoca 13 1 5
Klebsiella pneumoniae 26 44 7 2 1 1 2 1 84
Kluyvera sp. 1 1 2
Morganella morganii 12 3
Pantoea sp. 1 1
Proteus mirabilis 11 2
Pseudomonas aeruginosa 2 2 27 04 51 71 22 24 7 5 6 2 9 3
Pseudomonas putida 12 3
Pseudomonas stutzeri 11
Raoultella terrigena 1 1
Serratia marcescens 44 8
Stenotrophomonas maltophilia 11
Grand Total 1 68 135 51 82 52 23 14 23 65 82 596
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Page 5 of 8from 2004 to 2006 with VAP isolates [12]. The non-sus-
ceptible rate for imipenem in this study also is higher
than the 16.1% observed from 2000 to 2002 for P. aeru-
ginosa in both coronary and surgical ICU patients [13].
Against Enterobacteriaceae, doripenem and merope-
nem were equally active and at least four-fold more
active than imipenem. These results are consistent with
susceptibility data from the United Kingdom and Ireland
for 2001 to 2006 [14]. In addition, the activity of imipe-
nem and meropenem observed in Turkey in COMPACT
was very similar to the susceptibility rate of 97.6%
observed by Korten et al. for imipenem against all Entero-
bacteriaceae isolates from Turkey between 2000 and
2003 [15].
None of the 3 carbapenems showed good activity against
A. baumannii. This is not surprising given the high rates
of resistance observed overt h ep a s td e c a d ei nT u r k e y
[12,13]. The MIC90 for A. baumannii was several-fold
higher in this study than the MIC90 >8a n d>1 6m g / L
observed for imipenem and meropenem, respectively, in
Table 7 Isolates from Turkey: Meropenem MIC distribution
Number of isolates Meropenem E-test MIC (mg/L)
Species 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 > 32 Grand Total
Acinetobacter baumannii 1 1435558 2 1 5 3
Acinetobacter haemolyticus 11
Acinetobacter junii/johnsonii 11 1 3
Acinetobacter lwoffii 11
Citrobacter freundii 1 1
Enterobacter aerogenes 3 411 9
Enterobacter cloacae 11 6 1 9
Escherichia coli 3 50 39 16 3 2 2 115
Klebsiella oxytoca 12 2 5
Klebsiella pneumoniae 12 0 3 2 1 8 4 2 2 1 1 2 1 8 4
Kluyvera sp. 1 1 2
Morganella morganii 111 3
Pantoea sp. 1 1
Proteus mirabilis 11 2
Pseudomonas aeruginosa 3 12 40 38 31 23 16 20 27 9 31 43 293
Pseudomonas putida 21 3
Pseudomonas stutzeri 11
Raoultella terrigena 1 1
Serratia marcescens 1 2311 8
Stenotrophomonas maltophilia 11
Grand Total 5 79 91 54 53 45 36 30 23 26 32 15 41 66 596
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Figure 2 Cumulative% minimum inhibitory concentration (MIC)
distributions against Enterobacteriaceae (N = 240).
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Figure 3 Cumulative% minimum inhibitory concentration (MIC)
distributions against Acinetobacter baumannii (N = 53).
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Page 6 of 8the SENTRY Antimicrobial Surveillance Program from
2000 to 2006 in Ankara and Istanbul, Turkey [3].
The COMPACT surveillance study also was carried
out in 6 Asia-Pacific countries. As in the 10 centres in
Turkey and the 80 centres throughout Europe, the Mid-
dle East, and Africa, doripenem was the most active of
the carbapenems tested against Asia-Pacific isolates [16].
The MIC90 against all Asia-Pacific isolates was 8 mg/L
for doripenem compared with 32 mg/L for Turkey. The
mean MIC90 against all isolates for imipenem and mero-
penem (both ≥ 64 mg/L) was the same for Turkey and
the Asian-Pacific countries.
Conclusions
In conclusion, the carbapenems possess good activity
against the Gram-negative isolates included in this study,
including Pseudomonas spp. and Enterobacteriaceae,
among the 10 collecting centres in Turkey. Although the
rate of combined imipenem resistance, meropenem resis-
tance, or doripenem non-susceptibility was high in Turkey
and second only to Russia, doripenem was the most active
carbapenem against P. aeruginosa, was equally active to
meropenem, and was more active than imipenem against
Enterobacteriaceae.
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